G-FINDER
Overview
Neglected Diseases
In 2007, Policy Cures developed G-FINDER – an innovative survey to track global investments into neglected disease research and development (R&D). The findings are released as annual G-FINDER reports, starting in 2008, and available via a publicly-searchable database. G-FINDER is a uniquely informative data source, providing policy-makers, funders, researchers and industry with objective, previously unavailable information on the state of investment, trends and patterns:
- in 35 neglected diseases,
- across 142 product areas for these diseases including drugs, vaccines, diagnostics, microbicides and vector control products and
- in platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
The data includes all types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.
Reproductive Health
In 2014, Policy Cures reported on investment in reproductive health R&D for developing countries. The
G-FINDER Reproductive Health 2014 report provided, for the first time, comprehensive information on investment patterns:
- in six reproductive health areas as well as core funding to reproductive health R&D organisations
- covering drugs, diagnostics and devices
FUTURE REPORTS WILL BE AVAILABLE FROM POLICY CURES RESEARCH AT www.policycuresresearch.org
G-FINDER 2016
This report was jointly prepared by Policy Cures and Policy Cures Research
Download Report
G-FINDER 2014
- The G-FINDER Report 2014 - Neglected disease research and development: emerging trends
- The G-FINDER Reproductive Health Report 2014 - Reproductive health: R&D for the developing world
G-FINDER 2013
G-FINDER 2012
G-FINDER 2011
- The G-FINDER Report 2011 - Neglected disease research and development: is innovation under threat?
- G-FINDER highlights 2011 are also available in French, Spanish, and German.
G-FINDER 2010
G-FINDER 2009
G-FINDER 2008
Factsheets and in-depth reports
Government Funding for Neglected Diseases: Why it Doesn't Add Up
Every year, more than 6 million people in low- and middle-income countries die from neglected diseases, for which the vaccines, medicines and diagnostic tests are either ineffective or completely lacking. This factsheet reviews government funding of the research and development (R&D) needed to make these missing products, including:
- Which governments and agencies provide funding and how much
- Who gets the funding, and why this matters
- Why government funding for neglected disease R&D increasingly doesn’t add up
An Emerging Leader: Germany’s Role in Neglected and Poverty-related Disease R&D
Germany is now the fourth biggest public funder of neglected disease R&D globally in absolute terms however, in terms of its spend as a percentage of GDP (in 2012), it ranks below many other European countries including UK, France, Sweden, Ireland, the Netherlands and Switzerland.
Germany has a strong scientific history and a network of highly regarded research institutes active in R&D. As a G8 economy, Germany has the economic potential, unlike some of its European counterparts struggling to respond to the global economic crisis, to boost its neglected disease R&D funding and to capitalise on its R&D strengths. This report (also in German):
- Analyses German public funding from 2007-2012
- Gives a who’s-who of German public funders and research institutes
- Summarises neglected disease R&D achievements to date and funding opportunities for the future
G-FINDER Diagnostic R&D for Neglected Diseases
Effective diagnostics are essential tools for the control, elimination and eradication of neglected diseases, with the ability to quickly and accurately identify infections critical to ensuring that patients receive the treatment they need and halting the further spread of disease. One of the great challenges to monitoring disease emergence and delivering appropriate control measures is the lack of readily available, easy-to-use, reliable and low-cost diagnostic tools. Despite the pressing need for new diagnostics, and the obvious advantages to developing effective diagnostic tools, current funding levels for research and development of new diagnostics are insufficient to meet the needs of many neglected diseases.
This factsheet examines funding of diagnostic research and development globally, based on G-FINDER data, and discusses the urgent need to rationalise funding, diversify funding sources and increase priority driven investments.
Download Fact Sheet
G-FINDER R&D for Diarrhoeal Diseases
Diarrhoea is one of the six conditions identified in the fourth Millennium Development Goal: reduce child mortality, that lead to the majority of child deaths. In 2010, diarrhoeal diseases caused 1.1 million deaths and 66.5 million years of productive life lost in developing countries. Whilst preventive measures such as clean drinking water and sanitation can reduce the risk of infection, research and development (R&D) of new tools is equally important, particularly for vaccines as they can prevent infection.
This factsheet examines funding for diarrhoeal disease R&D globally from 2007-2011 and discusses the need to increase the focus on under-funded disease areas, diversify funding sources and balance funding distribution between basic research and product development.
Download Fact Sheet